£25.0M
EQT Ventures led the Series B round with participation from Parkwalk and Cambridge Innovation Capital.
"Commercial insurance underwriting is inaccurate and inefficient,"
Parkwalk
Venture CapitalParkwalk is a growth EIS fund manager that backs disruptive technologies emerging from the UK's leading universities and research institutions.
Recent investments
£1.5M
The follow-on investment will fund the commercial launch of new pancreatic and lung stem cell products.
"In a short space of time, DefiniGEN has undergone rapid development, securing growing sales with global pharma companies. We are delighted to have raised the funds that will allow us to deliver new market-leading products to our customers and assist them in developing therapies for the global healthcare challenges we face today such as diabetes and liver disease."
